-
Je něco špatně v tomto záznamu ?
Effect of Genetic Variation in CYP450 on Gonadal Impairment in a European Cohort of Female Childhood Cancer Survivors, Based on a Candidate Gene Approach: Results from the PanCareLIFE Study
MEM. van der Perk, L. Broer, Y. Yasui, LL. Robison, MM. Hudson, JSE. Laven, HJ. van der Pal, WJE. Tissing, B. Versluys, D. Bresters, GJL. Kaspers, ACH. de Vries, CB. Lambalk, A. Overbeek, JJ. Loonen, CCM. Beerendonk, J. Byrne, C. Berger, E....
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
NA
Stichting Kinder Oncologisch Centrum Rotterdam
NA
Princess Máxima Center Foundation
602030
Seventh Framework Programme
20
Stichting Kinderen Kankervrij
VU 2006-3622.
KWF Kankerbestrijding
U01 CA195547
NCI NIH HHS - United States
NLK
Directory of Open Access Journals
od 2010
Free Medical Journals
od 2009
PubMed Central
od 2009
Europe PubMed Central
od 2009
ProQuest Central
od 2009-01-01
Open Access Digital Library
od 2009-01-01
Open Access Digital Library
od 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2009
PubMed
34572825
DOI
10.3390/cancers13184598
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Female childhood cancer survivors (CCSs) carry a risk of therapy-related gonadal dysfunction. Alkylating agents (AA) are well-established risk factors, yet inter-individual variability in ovarian function is observed. Polymorphisms in CYP450 enzymes may explain this variability in AA-induced ovarian damage. We aimed to evaluate associations between previously identified genetic polymorphisms in CYP450 enzymes and AA-related ovarian function among adult CCSs. METHODS: Anti-Müllerian hormone (AMH) levels served as a proxy for ovarian function in a discovery cohort of adult female CCSs, from the pan-European PanCareLIFE cohort (n = 743; age (years): median 25.8, interquartile range (IQR) 22.1-30.6). Using two additive genetic models in linear and logistic regression, nine genetic variants in three CYP450 enzymes were analyzed in relation to cyclophosphamide equivalent dose (CED) score and their impact on AMH levels. The main model evaluated the effect of the variant on AMH and the interaction model evaluated the modifying effect of the variant on the impact of CED score on log-transformed AMH levels. Results were validated, and meta-analysis performed, using the USA-based St. Jude Lifetime Cohort (n = 391; age (years): median 31.3, IQR 26.6-37.4). RESULTS: CYP3A4*3 was significantly associated with AMH levels in the discovery and replication cohort. Meta-analysis revealed a significant main deleterious effect (Beta (95% CI): -0.706 (-1.11--0.298), p-value = 7 × 10-4) of CYP3A4*3 (rs4986910) on log-transformed AMH levels. CYP2B6*2 (rs8192709) showed a significant protective interaction effect (Beta (95% CI): 0.527 (0.126-0.928), p-value = 0.01) on log-transformed AMH levels in CCSs receiving more than 8000 mg/m2 CED. CONCLUSIONS: Female CCSs CYP3A4*3 carriers had significantly lower AMH levels, and CYP2B6*2 may have a protective effect on AMH levels. Identification of risk-contributing variants may improve individualized counselling regarding the treatment-related risk of infertility and fertility preservation options.
Boyne Research Institute 5 Bolton Square East Drogheda A92 RY6K Co Louth Ireland
Childhood Cancer Research Group Danish Cancer Society Research Center 2100 Copenhagen Denmark
Department of Epidemiology Netherlands Cancer Institute 1066 CX Amsterdam The Netherlands
Department of Haematology Radboud University Medical Center 6500 HB Nijmegen The Netherlands
Department of Intelligent Systems Delft University of Technology 2628 BL Delft The Netherlands
Department of Oncology Oslo University Hospital 0372 Oslo Norway
Department of Paediatric Oncology University Hospital 42 055 Saint Etienne France
Division of Clinical Pharmacology Children's National Hospital Washington DC 20010 USA
German Cancer Research Centre DKTK Site Essen 45147 Essen Germany
Lyon University Jean Monnet University INSERM U 1059 Sainbiose 42023 Saint Etienne France
Motol University Hospital 150 05 Prague Czech Republic
Princess Máxima Center for Pediatric Oncology 3584 CS Utrecht The Netherlands
University Hospital Essen Pediatrics 3 West German Cancer Centre 45147 Essen Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21023946
- 003
- CZ-PrNML
- 005
- 20211013134110.0
- 007
- ta
- 008
- 211006s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/cancers13184598 $2 doi
- 035 __
- $a (PubMed)34572825
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a van der Perk, M E Madeleine $u Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands
- 245 10
- $a Effect of Genetic Variation in CYP450 on Gonadal Impairment in a European Cohort of Female Childhood Cancer Survivors, Based on a Candidate Gene Approach: Results from the PanCareLIFE Study / $c MEM. van der Perk, L. Broer, Y. Yasui, LL. Robison, MM. Hudson, JSE. Laven, HJ. van der Pal, WJE. Tissing, B. Versluys, D. Bresters, GJL. Kaspers, ACH. de Vries, CB. Lambalk, A. Overbeek, JJ. Loonen, CCM. Beerendonk, J. Byrne, C. Berger, E. Clemens, U. Dirksen, J. Falck Winther, SD. Fosså, D. Grabow, M. Muraca, M. Kaiser, T. Kepák, J. Kruseova, D. Modan-Moses, C. Spix, O. Zolk, P. Kaatsch, JH. Krijthe, LCM. Kremer, RJ. Brooke, JL. Baedke, RHN. van Schaik, JN. van den Anker, AG. Uitterlinden, AME. Bos, FE. van Leeuwen, E. van Dulmen-den Broeder, ALF. van der Kooi, MM. van den Heuvel-Eibrink, . On Behalf Of The PanCareLIFE Consortium
- 520 9_
- $a BACKGROUND: Female childhood cancer survivors (CCSs) carry a risk of therapy-related gonadal dysfunction. Alkylating agents (AA) are well-established risk factors, yet inter-individual variability in ovarian function is observed. Polymorphisms in CYP450 enzymes may explain this variability in AA-induced ovarian damage. We aimed to evaluate associations between previously identified genetic polymorphisms in CYP450 enzymes and AA-related ovarian function among adult CCSs. METHODS: Anti-Müllerian hormone (AMH) levels served as a proxy for ovarian function in a discovery cohort of adult female CCSs, from the pan-European PanCareLIFE cohort (n = 743; age (years): median 25.8, interquartile range (IQR) 22.1-30.6). Using two additive genetic models in linear and logistic regression, nine genetic variants in three CYP450 enzymes were analyzed in relation to cyclophosphamide equivalent dose (CED) score and their impact on AMH levels. The main model evaluated the effect of the variant on AMH and the interaction model evaluated the modifying effect of the variant on the impact of CED score on log-transformed AMH levels. Results were validated, and meta-analysis performed, using the USA-based St. Jude Lifetime Cohort (n = 391; age (years): median 31.3, IQR 26.6-37.4). RESULTS: CYP3A4*3 was significantly associated with AMH levels in the discovery and replication cohort. Meta-analysis revealed a significant main deleterious effect (Beta (95% CI): -0.706 (-1.11--0.298), p-value = 7 × 10-4) of CYP3A4*3 (rs4986910) on log-transformed AMH levels. CYP2B6*2 (rs8192709) showed a significant protective interaction effect (Beta (95% CI): 0.527 (0.126-0.928), p-value = 0.01) on log-transformed AMH levels in CCSs receiving more than 8000 mg/m2 CED. CONCLUSIONS: Female CCSs CYP3A4*3 carriers had significantly lower AMH levels, and CYP2B6*2 may have a protective effect on AMH levels. Identification of risk-contributing variants may improve individualized counselling regarding the treatment-related risk of infertility and fertility preservation options.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Broer, Linda $u Department of Internal Medicine, Rotterdam, ErasmusMC University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
- 700 1_
- $a Yasui, Yutaka $u Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
- 700 1_
- $a Robison, Leslie L $u Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
- 700 1_
- $a Hudson, Melissa M $u Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN 38105, USA $u Department of Oncology, Division of Survivorship, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
- 700 1_
- $a Laven, Joop S E $u Department of Obstetrics and Gynecology, Erasmus MC-University Medical Center, 3015 GD Rotterdam, The Netherlands
- 700 1_
- $a van der Pal, Helena J $u Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands
- 700 1_
- $a Tissing, Wim J E $u Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands
- 700 1_
- $a Versluys, Birgitta $u Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands
- 700 1_
- $a Bresters, Dorine $u Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands
- 700 1_
- $a Kaspers, Gertjan J L $u Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands $u Department of Pediatric Oncology-Haematology, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, 1105 AZ Amsterdam, The Netherlands
- 700 1_
- $a de Vries, Andrica C H $u Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands
- 700 1_
- $a Lambalk, Cornelis B $u Department of Obstetrics and Gynaecology, Amsterdam UMC, Vrije Universiteit Amsterdam, 1105 AZ Amsterdam, The Netherlands
- 700 1_
- $a Overbeek, Annelies $u Department of Obstetrics and Gynaecology, Amsterdam UMC, Vrije Universiteit Amsterdam, 1105 AZ Amsterdam, The Netherlands
- 700 1_
- $a Loonen, Jacqueline J $u Department of Haematology, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands
- 700 1_
- $a Beerendonk, Catharina C M $u Department of Obstetrics and Gynaecology, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands
- 700 1_
- $a Byrne, Julianne $u Boyne Research Institute, 5 Bolton Square, East, Drogheda, A92 RY6K Co. Louth, Ireland
- 700 1_
- $a Berger, Claire $u Department of Paediatric Oncology, University Hospital, 42 055 Saint-Etienne, France $u Lyon University, Jean Monnet University, INSERM, U 1059, Sainbiose, 42023 Saint-Etienne, France
- 700 1_
- $a Clemens, Eva $u Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands
- 700 1_
- $a Dirksen, Uta $u University Hospital Essen, Pediatrics III, West German Cancer Centre, 45147 Essen, Germany $u German Cancer Research Centre, DKTK, Site Essen, 45147 Essen, Germany
- 700 1_
- $a Falck Winther, Jeanette $u Childhood Cancer Research Group, Danish Cancer Society Research Center, 2100 Copenhagen, Denmark $u Department of Clinical Medicine, Faculty of Health, Aarhus University and University Hospital, 8200 Aarhus, Denmark
- 700 1_
- $a Fosså, Sophie D $u Department of Oncology, Oslo University Hospital, 0372 Oslo, Norway
- 700 1_
- $a Grabow, Desiree $u Division of Childhood Cancer Epidemiology, German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany
- 700 1_
- $a Muraca, Monica $u Epidemiology and Biostatistics Unit and DOPO Clinic, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy
- 700 1_
- $a Kaiser, Melanie $u Division of Childhood Cancer Epidemiology, German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany
- 700 1_
- $a Kepák, Tomáš $u University Hospital Brno, International Clinical Research Center (FNUSA-ICRC), Masaryk University, 656 91 Brno, Czech Republic
- 700 1_
- $a Kruseova, Jarmila $u Motol University Hospital, 150 05 Prague, Czech Republic
- 700 1_
- $a Modan-Moses, Dalit $u The Edmond and Lily Safra Children's Hospital, Chaim Sheba Medical Center, Tel Hashomer, and the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 6997801, Israel
- 700 1_
- $a Spix, Claudia $u Division of Childhood Cancer Epidemiology, German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany
- 700 1_
- $a Zolk, Oliver $u Institute of Clinical Pharmacology, Brandenburg Medical School Theodor Fontane, Immanuel Klinik Rüdersdorf, 16816 Neuruppin, Germany
- 700 1_
- $a Kaatsch, Peter $u Division of Childhood Cancer Epidemiology, German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes Gutenberg University Mainz, 55131 Mainz, Germany
- 700 1_
- $a Krijthe, Jesse H $u Department of Intelligent Systems, Delft University of Technology, 2628 BL Delft, The Netherlands
- 700 1_
- $a Kremer, Leontien C M $u Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands
- 700 1_
- $a Brooke, Russell J $u Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
- 700 1_
- $a Baedke, Jessica L $u Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
- 700 1_
- $a van Schaik, Ron H N $u Department of clinical chemistry, Erasmus MC University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
- 700 1_
- $a van den Anker, John N $u Division of Clinical Pharmacology, Children's National Hospital, Washington, DC 20010, USA
- 700 1_
- $a Uitterlinden, André G $u Department of Internal Medicine, Rotterdam, ErasmusMC University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
- 700 1_
- $a Bos, Annelies M E $u Department of Reproductive Medicine and Gynecology, University Medical Center Utrecht, 3584 CS Utrecht, The Netherlands
- 700 1_
- $a van Leeuwen, Flora E $u Department of Epidemiology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands
- 700 1_
- $a van Dulmen-den Broeder, Eline $u Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands
- 700 1_
- $a van der Kooi, Anne-Lotte L F $u Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands $u Department of Obstetrics and Gynecology, Erasmus MC-University Medical Center, 3015 GD Rotterdam, The Netherlands
- 700 1_
- $a van den Heuvel-Eibrink, Marry M $u Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands
- 700 1_
- $a On Behalf Of The PanCareLIFE Consortium,
- 773 0_
- $w MED00173178 $t Cancers $x 2072-6694 $g Roč. 13, č. 18 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34572825 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20211006 $b ABA008
- 991 __
- $a 20211013134107 $b ABA008
- 999 __
- $a ind $b bmc $g 1708140 $s 1144440
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 13 $c 18 $e 20210913 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
- GRA __
- $a NA $p Stichting Kinder Oncologisch Centrum Rotterdam
- GRA __
- $a NA $p Princess Máxima Center Foundation
- GRA __
- $a 602030 $p Seventh Framework Programme
- GRA __
- $a 20 $p Stichting Kinderen Kankervrij
- GRA __
- $a VU 2006-3622. $p KWF Kankerbestrijding
- GRA __
- $a U01 CA195547 $p NCI NIH HHS $2 United States
- LZP __
- $a Pubmed-20211006
